Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases
Sivan Schipper,Kabir Nigam,Yasmin Schmid,Vanessa Piechotta,Michael Ljuslin,Yvan Beaussant,Guido Schwarzer,Christopher Boehlke
DOI: https://doi.org/10.1002/14651858.cd015383.pub2
IF: 8.4
2024-09-13
Cochrane Database of Systematic Reviews
Abstract:Psychedelic‐assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians, psychologists, and others. It has been hypothesised that psychedelic‐assisted therapy may reduce symptoms of anxiety, depression, and existential distress in patients facing life‐threatening diseases (e.g. cancer). However, these substances are illegal in most countries and have been associated with potential risks. To assess the benefits and harms of psychedelic‐assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in people with life‐threatening diseases. We searched CENTRAL, MEDLINE, Embase, and two trial registers on 30 March 2024. In addition, we undertook reference checking, citation searching, and contact with study authors to identify additional studies. We used no language or date restrictions. We included randomised controlled trials (RCTs), with no restrictions regarding comorbidity, sex, or ethnicity. Interventions comprised a substance‐induced psychedelic experience preceded by preparatory therapeutic sessions and followed by integrative therapeutic sessions. We used the standard methodological procedures expected by Cochrane. We included six studies in the review, which evaluated two different interventions: psychedelic‐assisted therapy with classical psychedelics (psilocybin ('magic mushrooms') and lysergic acid diethylamide (LSD)), and psychedelic‐assisted therapy with 3,4‐methylenedioxymethamphetamine (MDMA or 'Ecstasy'). The studies randomised 149 participants with life‐threatening diseases and analysed data for 140 of them. The age range of participants was 36 to 64 years. The studies lasted between 6 and 12 months, and were conducted in outpatient settings in the USA and in Switzerland. Drug companies were not involved in study funding, but funding was provided by organisations that promote psychedelic‐assisted therapy. Primary outcomes (at 1 to 12 weeks) Anxiety Psychedelic‐assisted therapy using classical psychedelics (psilocybin, LSD) may result in a reduction in anxiety when compared to active placebo (or low‐dose psychedelic): State Trait Anxiety Inventory (STAI‐Trait, scale 20 to 80) mean difference (MD) −8.41, 95% CI −12.92 to −3.89; STAI‐State (scale 20 to 80) MD −9.04, 95% CI −13.87 to −4.21; 5 studies, 122 participants; low‐certainty evidence. The effect of psychedelic‐assisted therapy using MDMA on anxiety, compared to placebo, is very uncertain: STAI‐T MD −14.70, 95% CI −29.45 to 0.05; STAI‐S MD −16.10, 95% CI −33.03 to 0.83; 1 study, 18 participants; very low certainty evidence. Depression Psychedelic‐assisted therapy using classical psychedelics (psilocybin, LSD) may result in a reduction in depression when compared to active placebo (or low‐dose psychedelic): Beck Depression Inventory (BDI, scale 0 to 63) MD −4.92, 95% CI −8.97 to −0.87; 4 studies, 112 participants; standardised mean difference (SMD) −0.43, 95% CI −0.79 to −0.06; 5 studies, 122 participants; low‐certainty evidence. The effect of psychedelic‐assisted therapy using MDMA on depression, compared to placebo, is very uncertain: BDI‐II (scale: 0 to 63) MD −6.30, 95% CI −16.93 to 4.33; 1 study, 18 participants; very low certainty evidence. Existential distress Psychedelic‐assisted therapy using classical psychedelics (psilocybin, LSD) compared to active placebo (or low‐dose psychedelic) may result in a reduction in demoralisation, one of the most common measures of existential distress, but the evidence is very uncertain (Demoralisation Scale, 1 study, 28 participants): post treatment scores, placebo group 39.6 (SEM 3.4), psilocybin group 18.8 (3.6), P ≤ 0.01). Evidence from other measures of existential distress was mixed. Existential distress was not measured in people receiving psychedelic‐assisted therapy with MDMA . Secondary outcomes (at 1 to 12 weeks) Quality of life When classical psychedelics were used, one study had inconclusive results and two reported improved quality of life, but the evidence is very uncertain. MDMA did not improve quality of life measures, but the evidence is also very uncertain. Spirituality Participants receiving psychedelic‐assisted therapy with classical psychedelics rated their experience as being spiritually significant (2 studies), but the evidence is very uncertain. Spirituality was not assessed in participants receiving MDMA . Adverse events No treatment‐related serious adverse events or adverse events grade 3/4 were reported. Common minor to moderate adverse events for classical psychedelics were elevated blood pressure, nausea, anxiety, emotional distress, and psychotic‐like symptoms (e.g. pseudo‐hallucination where the participant is aware they -Abstract Truncated-
medicine, general & internal